ClinicalTrials.gg
CompletedNCT03452501Updated Feb 23, 2021

Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients

An observational study in Inflammatory Bowel Diseases, Crohn Disease and Fistulizing Crohn's Disease, sponsored by Hikma Pharmaceuticals LLC. Completed at 4 sites in Saudi Arabia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-23.

Sponsored by Hikma Pharmaceuticals LLC · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
157
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this observational study is to assess the safety and effectiveness of biosimilar Infliximab in patients with inflammatory bowel disease (IBD) in Saudi Arabia where no visits or intervention(s) additional to the daily practice will be performed.

Read the detailed description

A multicenter, observational, prospective, cohort study to assess the safety and effectiveness of biosimilar Infliximab (Remsima®) in newly diagnosed and in switched IBD patients diagnosed with active Crohn's disease (CD), fistulizing CD, or Ulcerative Colitis (UC). Each patient is expected to be treated for a total of 38 weeks if naive or 40 weeks if switched. The study duration will be between 46 and 48 weeks (up to 12 months). Follow-up is expected to end 8 weeks after the last treatment visit.

02

Conditions studied

  • Inflammatory Bowel Diseases
  • Crohn Disease
  • Fistulizing Crohn's Disease
  • Ulcerative Colitis

Keywords

  • Infliximab
  • Remsima
  • Biosimilar
  • Inflammatory Bowel Diseases
  • Crohn's Disease
  • Ulcerative Colitis
  • Fistulizing Crohn's Disease
  • Observational
  • Follow up
  • Safety
  • Effectiveness
  • Disease modifying anti-rheumatic drugs
  • Tumor necrosis factor-alpha inhibitors
03

In context

Inflammatory Bowel Diseases

1,552 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.

This study's enrollment of 157 is above the median of 140 across 626 observational studies indexed under Inflammatory Bowel Diseases.

Browse Inflammatory Bowel Diseases studies →

Lead sponsor

Hikma Pharmaceuticals LLC is the lead sponsor of 14 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be recruited from approximately 6 sites in Saudi Arabia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Adult patients with moderate to severe active CD who have not responded despite a full and adequate course of therapy with and/or agents, or who are intolerant to or have medical to such therapies.
  • Adult patients with fistulizing active CD who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).
  • Adult patients with moderate to severe active UC who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant or have medical contraindications to such therapies.
  • Switched patients who received at least one dose of Infliximab reference medicinal product (RMP) before the first infusion of Remsima®.
  • Patients who agree to join the study and give a written

Exclusion criteria

Exclusion Criteria:

    • Patients with a known history of to infliximab, to other murine proteins, or to any of the (Sucrose, Polysorbate 80, Monobasic sodium phosphate and/or Dibasic sodium phosphate).
  • Patients who have shown intolerance or inefficacy to biologics for IBD treatment.
  • Female patients who are known to be pregnant or breastfeeding.
  • Patients with a past or present history of chronic infection with , , or (HIV), or those with positive test at screening.
  • Patients who are diagnosed with tuberculosis (TB) or previously diagnosed with TB with no evidence of complete resolution
  • Patients with severe or chronic infections (e.g. sepsis, abscesses, opportunistic infections, invasive fungal infections), or severe or chronic infection, without sufficient documentation of complete resolution following treatment
  • Patients with recent exposure to persons with active TB, or a positive test result for latent TB at Screening. A patient who has received at least the first 30 days or recommended period of country-specific TB prophylactic therapy and intends to complete the entire course of therapy may be enrolled. Recommended methods to screening latent TB are interferon-γ release assay [IGRA] test, with a chest X-ray, however, other methods could be used according to local guideline.
  • Patients with moderate or severe heart failure ( NYHA class III/IV).
  • Patients for whom the treatment with Tumor necrosis factor-alpha (TNF-α) blockers is concerning due to a history of within the previous five years prior to enrollment or a history of herpes zoster within one month prior to enrollment, may be excluded at the investigator's discretion.
  • Patients who meet any of the to the administration of infliximab
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
157 participants (actual)
Patient registry
No

Groups and cohorts

  • Naïve group

    Newly diagnosed patients

    Drug: Infliximab

  • Switched group

    Patients who received at least one dose of Infliximab reference medicinal product (RMP) before the first infusion of Remsima®

    Drug: Infliximab

Interventions

  • A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg

    Also known as: Remsima®

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs) to Remsima®

    Number, type, severity and frequency of adverse events (AEs), serious AEs (SAEs), and clinically relevant changes in laboratory tests (according to laboratory reference ranges), in addition to the incidence of latent tuberculosis (TB) activation (as an adverse event) and the incidence of hepatitis B virus HBV, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) will be assessed

    Time frame: 12 months

Secondary outcomes

  1. Proportions of naïve patients with CD achieving clinical response or remission based on Crohn's Disease Activity Index (CDAI)

    Clinical response is defined by a decrease in CDAI score from baseline of at least 70 points (Response-70). Clinical remission score \< 150 for naïve patients with CD

    Time frame: Up to 12 months

  2. Proportion of switched patients with CD achieving disease control

    Disease control is defined as the absence of disease worsening, with worsening defined as increase in CDAI of 70 points or more from the qualifying score with a total score of 175 or more and an increase in CDAI of 35% or more from baseline, or the introduction of a new treatment for active CD

    Time frame: Up to 12 months

  3. Proportion of naïve patients with fistulizing CD achieving clinical response or remission

    Clinical response is defined as reduction of at least 50% from baseline in the number of draining fistulas. Clinical remission is defined as the absence of draining fistulas

    Time frame: Up to 12 months

  4. Proportion of switched patients with fistulizing CD achieving disease control

    Disease control is defined as no loss of response, with loss of response defined as the recrudescence of draining fistulas, the need for a change in medication for CD, the need for additional therapy for persistent or worsening luminal disease activity, the need for a surgical procedure for CD, or the discontinuation of study medication owing to a perceived lack of effectiveness

    Time frame: Up to 12 months

  5. Proportion of naïve patients with UC achieving clinical response or remission based on Partial Mayo Score and mucosal healing

    Clinical response is defined as a decrease in partial Mayo scores from baseline of 2 points or more and 30% or more, with an accompanying decrease in the subscore for rectal bleeding of 1 point or more, or an absolute subscore for rectal bleeding of 0 or 1). Clinical remission is defined as a total partial Mayo score of 2 points or less, with no individual sub-score of more than 1 point), Mucosal healing (assessed through endoscopy, and defined by Mayo endoscopic subscore of 1 point or less)

    Time frame: Up to 12 months

  6. Proportion of switched patients with UC achieving disease control.

    Disease control is defined as the absence of disease worsening, with worsening defined by an increase in partial Mayo score of 3 points or more from baseline \[before switching\] and a partial Mayo score of 5 points or more).

    Time frame: Up to 12 months

07

Study locations

4 sites
  • King Abdulaziz University Hospital
    Jeddah, Saudi Arabia
  • Prince Sultan Military Medical City
    Riyadh, 11159, Saudi Arabia
  • King Abdullah International Medical Research Center
    Riyadh, 11426, Saudi Arabia
  • King Saud Medical City
    Riyadh, Saudi Arabia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Aug 2020, 23 months.

Of 37 industry-sponsored observational studies under Inflammatory Bowel Diseases, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 44. This study's 23 months is below that.

Counting every sponsor, half of 281 studies reached it within 36 months; a quarter within 20 and three quarters within 122.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2018
First posted
Mar 2, 2018
StartActual
Aug 26, 2018
Primary completionActual
Aug 17, 2020
CompletionActual
Aug 17, 2020
Last update
Feb 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03452501
Responsible party
Sponsor
First posted
Mar 2, 2018
Start date
Aug 26, 2018
Primary completion
Aug 17, 2020
Completion
Aug 17, 2020
Last update
Feb 23, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion